902 ORAL Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

Abstract

Lung cancer is one of the leading causes of cancer-related death worldwide. Conventional lung cancer therapy is lacking specificity, targeting both normal and cancer cells and leading to cytotoxicity, drug resistance, reduced cellular uptake, and rapid drug clearance from the body. Treatment of lung cancer has seen a great revolution with the emergence of nanotechnology. Nanotechnology-based lung cancer treatment is focused on targeting tumor cells without interrupting normal cell function and improves bioavailability and reduces the toxicity of anticancer drugs. In recent years, nanocarrier-based drug delivery systems have been extensively used to overcome the barriers in lung cancer treatment. These systems have revealed great therapeutic potential for lung cancer therapy due to their unique selective targeting to tumor cells via their smaller size and surface modifications. In addition, pulmonary delivery of nanocarriers is gaining significant interest in recent years because lungs have a large absorptive surface area, good blood supply, and a relatively thin absorptive mucosal membrane. In this chapter, various nanocarrier-based drug delivery systems for lung cancer treatment are discussed, with a special focus on their pulmonary delivery. Various approaches and obstacles in pulmonary drug delivery are also discussed.